Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer

被引:25
|
作者
Ji, Huihui [1 ]
Zhang, Jian-an [1 ]
Liu, Hejing [1 ]
Li, Kehan [1 ]
Wang, Zhi-wei [1 ]
Zhu, Xueqiong [1 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 2, Ctr Uterine Canc Diag & Therapy Res Zhejiang Prov, Dept Obstet & Gynecol, Wenzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
cervical cancer; M6A; TME; PD-1; PD-L1; TIME; MESSENGER-RNA; CELLS;
D O I
10.3389/fimmu.2022.976107
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Understanding the role of N6-adenosine methylation (m6A) in the tumor microenvironment (TME) is important since it can contribute to tumor development. However, the research investigating the association between m6A and TME and cervical cancer is still in its early stages. The aim of this study was to discover the possible relationship between m6A RNA methylation regulators, TME, PD-L1 expression levels, and immune infiltration in cervical cancer. We gathered RNA-seq transcriptome data and clinical information from cervical cancer patients using The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. To begin, researchers assessed the differences in m6A regulatory factor expression levels between cervical cancer and normal tissues. Clustering analysis was adapted to assess PD-L1 expression, immunological score, immune cell infiltration, TME, and probable pathways in cervical cancer samples. The majority of m6A regulators were found to be considerably overexpressed in cervical cancer tissues. Using consensus clustering of 21 m6A regulators, we identified two subtypes (clusters 1/2) of cervical cancer, and we found that WHO stage and grade were associated with the subtypes. PD-L1 expression increased dramatically in cervical cancer tissues and was significantly linked to ALKBH5, FTO, METTL3, RBM15B, YTHDF1, YTHDF3, and ZC3H13 expression levels. Plasma cells and regulatory T cells (Tregs) were considerably elevated in cluster 2. Cluster 1 is involved in numerous signature pathways, including basal transcription factors, cell cycle, RNA degradation, and the spliceosome. The prognostic signature-based riskscore (METTL16, YTHDF1, and ZC3H13) was found to be an independent prognostic indicator of cervical cancer. The tumor immune microenvironment (TIME) was linked to m6A methylation regulators, and changes in their copy number will affect the quantity of tumor-infiltrating immune cells dynamically. Overall, our research discovered a powerful predictive signature based on m6A RNA methylation regulators. This signature correctly predicted the prognosis of cervical cancer patients. The m6A methylation regulator could be a critical mediator of PD-L1 expression and immune cell infiltration, and it could have a significant impact on the TIME of cervical cancer.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Association of Expression of PD-L1 with the Tumor Immune Microenvironment in Small Cell Lung Cancer
    Yu, Hui
    Badzio, Andrzej
    Boyle, Theresa A.
    Chan, Dan
    Rivard, Christopher J.
    Lu, Xian
    Kowalewski, Ashley A.
    Ellison, Kim
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S222 - S223
  • [22] Characterization of m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration in Ovarian Cancer
    Luo, Yihong
    Sun, Xiang
    Xiong, Jian
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 9
  • [23] m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer
    Zhang, Bo
    Wu, Qiong
    Li, Ben
    Wang, Defeng
    Wang, Lei
    Zhou, You Lang
    MOLECULAR CANCER, 2020, 19 (01)
  • [24] Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma
    Wang, Lianzi
    Zhang, Shubing
    Li, Huimin
    Xu, Yang
    Wu, Qiang
    Shen, Jilong
    Li, Tao
    Xu, Yuanhong
    BMC CANCER, 2021, 21 (01)
  • [25] LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma
    Wang, Houhong
    Tang, Amao
    Cui, Yayun
    Gong, Huihui
    Li, Heng
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [26] Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
    Weyerer, Veronika
    Strissel, Pamela L.
    Strick, Reiner
    Sikic, Danijel
    Geppert, Carol I.
    Bertz, Simone
    Lange, Fabienne
    Taubert, Helge
    Wach, Sven
    Breyer, Johannes
    Bolenz, Christian
    Erben, Philipp
    Schmitz-Draeger, Bernd J.
    Wullich, Bernd
    Hartmann, Arndt
    Eckstein, Markus
    CANCERS, 2021, 13 (10)
  • [27] Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
    Lin, Weimin
    Chen, Miao
    Hong, Le
    Zhao, Hang
    Chen, Qianming
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [28] Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation
    Quan, Yongjun
    Zhang, Xiaodong
    Ping, Hao
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [29] Comprehensive analysis of the PD-L1 and immune infiltrates of N6-methyladenosine related long non-coding RNAs in bladder cancer
    Xue, M. Q.
    Wang, Y. L.
    Wang, J. C.
    Wang, X. D.
    Wang, X. J.
    Zhang, Y. Q.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [30] m6A Regulator-Based Methylation Modification Patterns Characterized by Distinct Tumor Microenvironment Immune Profiles in Rectal Cancer
    Liao, Kaili
    Hu, Jialing
    Huang, Yu
    Yu, Siji
    Yang, Qijun
    Sun, Fan
    Wu, Chengfeng
    Cheng, Yunqi
    Zhang, Wenyige
    Zhang, Xue
    Li, Hongyu
    Wang, Xiaozhong
    FRONTIERS IN ONCOLOGY, 2022, 12